DE69108200T2 - 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1). - Google Patents

3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1).

Info

Publication number
DE69108200T2
DE69108200T2 DE69108200T DE69108200T DE69108200T2 DE 69108200 T2 DE69108200 T2 DE 69108200T2 DE 69108200 T DE69108200 T DE 69108200T DE 69108200 T DE69108200 T DE 69108200T DE 69108200 T2 DE69108200 T2 DE 69108200T2
Authority
DE
Germany
Prior art keywords
indole
dimethylamino
methyl
ethyl
methanesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69108200T
Other languages
German (de)
English (en)
Other versions
DE69108200D1 (de
Inventor
Joanne Ware Hertfordshire Sg12 0Dg Craig
Derek Leslie Ware Hertfordshire Sg12 0Dg Crookes
Stephen John Ware Hertfordshire Sg12 0Dg Skittrall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE69108200D1 publication Critical patent/DE69108200D1/de
Publication of DE69108200T2 publication Critical patent/DE69108200T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
DE69108200T 1990-12-12 1991-12-12 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1). Expired - Lifetime DE69108200T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (2)

Publication Number Publication Date
DE69108200D1 DE69108200D1 (de) 1995-04-20
DE69108200T2 true DE69108200T2 (de) 1995-07-20

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69108200T Expired - Lifetime DE69108200T2 (de) 1990-12-12 1991-12-12 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1).

Country Status (36)

Country Link
US (2) US5554639A (enExample)
EP (1) EP0490689B1 (enExample)
JP (1) JP2994037B2 (enExample)
KR (1) KR100211479B1 (enExample)
CN (2) CN1030890C (enExample)
AP (1) AP230A (enExample)
AT (1) ATE119881T1 (enExample)
AU (1) AU650706B2 (enExample)
BE (1) BE1005085A3 (enExample)
CA (1) CA2098302C (enExample)
CH (1) CH684192A5 (enExample)
CY (1) CY2005A (enExample)
CZ (1) CZ281931B6 (enExample)
DE (1) DE69108200T2 (enExample)
DK (1) DK0490689T3 (enExample)
EG (1) EG20219A (enExample)
ES (1) ES2069836T3 (enExample)
FR (1) FR2670487B1 (enExample)
GB (2) GB9026998D0 (enExample)
GR (1) GR3015430T3 (enExample)
HK (1) HK82697A (enExample)
HU (1) HU211937A9 (enExample)
IE (1) IE62894B1 (enExample)
IL (1) IL100330A (enExample)
IS (1) IS1706B (enExample)
IT (1) IT1252868B (enExample)
MX (1) MX9102501A (enExample)
MY (1) MY109265A (enExample)
NL (1) NL9102071A (enExample)
NZ (1) NZ240942A (enExample)
PT (1) PT99757B (enExample)
RU (1) RU2108328C1 (enExample)
TW (2) TW300886B (enExample)
WO (1) WO1992010477A1 (enExample)
YU (1) YU48926B (enExample)
ZA (1) ZA919750B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318212T2 (de) * 1992-06-05 1998-11-19 Merck Sharp & Dohme Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
WO2003032983A1 (en) * 2001-06-05 2003-04-24 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
EP1575566B1 (en) * 2002-12-26 2012-02-22 Pozen, Inc. Multilayer dosage forms containing naproxen and triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050269402A1 (en) * 2004-06-03 2005-12-08 Tyfone, Inc. System and method for securing financial transactions
EP1765300A2 (en) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007014613A (es) 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
US8580791B2 (en) 2008-05-27 2013-11-12 Biota Scientific Management Pty Ltd Antiviral 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole bis-dihydrogen-phosphate salts
US8618157B2 (en) * 2008-06-20 2013-12-31 Alphapharm Pty. Ltd. Pharmaceutical formulation
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
EP2296652B1 (en) * 2008-06-30 2017-11-08 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
KR101646079B1 (ko) 2009-09-25 2016-08-12 닥터 레디스 레보러터리즈 리미티드 트립탄 화합물을 포함하는 제제
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
EP3294339B1 (en) 2015-05-15 2020-12-02 The Regents Of The University Of Michigan Methods and compositions for the treatment of arthritis
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
KR102925234B1 (ko) 2017-11-07 2026-02-09 더 리젠츠 오브 더 유니버시티 오브 미시건 공유 에피토프-칼레티쿨린 상호 작용의 소분자 억제제 및 사용 방법
US20220096438A1 (en) 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
MX2022010407A (es) * 2020-02-27 2022-11-07 Biohaven Pharm Holding Co Ltd Forma de dosis oral de rápida dispersión de rimegepant.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
EG20219A (en) 1997-11-30
BE1005085A3 (fr) 1993-04-13
IS1706B (is) 1998-12-10
DE69108200D1 (de) 1995-04-20
EP0490689B1 (en) 1995-03-15
AU9072091A (en) 1992-07-08
FR2670487A1 (fr) 1992-06-19
PT99757A (pt) 1992-12-31
ES2069836T3 (es) 1995-05-16
GB2251614B (en) 1994-12-14
CN1063099A (zh) 1992-07-29
AP230A (en) 1993-01-27
ATE119881T1 (de) 1995-04-15
HK82697A (en) 1997-06-27
GB2251614A (en) 1992-07-15
KR100211479B1 (ko) 1999-08-02
CN1030890C (zh) 1996-02-07
CN1050831C (zh) 2000-03-29
CZ114093A3 (en) 1994-02-16
JP2994037B2 (ja) 1999-12-27
IE62894B1 (en) 1995-03-08
IL100330A (en) 1996-06-18
RU2108328C1 (ru) 1998-04-10
IL100330A0 (en) 1992-09-06
GB9026998D0 (en) 1991-01-30
ITRM910922A1 (it) 1993-06-11
IT1252868B (it) 1995-06-28
US5705520A (en) 1998-01-06
ITRM910922A0 (it) 1991-12-11
HU211937A9 (en) 1996-01-29
MX9102501A (es) 1992-09-01
WO1992010477A1 (en) 1992-06-25
CA2098302C (en) 2001-10-16
ZA919750B (en) 1992-10-28
CN1128259A (zh) 1996-08-07
CZ281931B6 (cs) 1997-04-16
YU48926B (sh) 2002-12-10
AP9100339A0 (en) 1992-01-31
YU191491A (sh) 1994-04-05
MY109265A (en) 1996-12-31
CY2005A (en) 1997-12-05
PT99757B (pt) 1999-05-31
IE914317A1 (en) 1992-06-17
GR3015430T3 (en) 1995-06-30
DK0490689T3 (da) 1995-05-22
FR2670487B1 (fr) 1993-08-20
NL9102071A (nl) 1992-07-01
TW205035B (enExample) 1993-05-01
CA2098302A1 (en) 1992-06-13
US5554639A (en) 1996-09-10
AU650706B2 (en) 1994-06-30
NZ240942A (en) 1994-03-25
IS3790A7 (is) 1992-06-13
GB9126297D0 (en) 1992-02-12
JPH06503560A (ja) 1994-04-21
CH684192A5 (fr) 1994-07-29
EP0490689A1 (en) 1992-06-17
TW300886B (enExample) 1997-03-21

Similar Documents

Publication Publication Date Title
DE69108200T2 (de) 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1).
DE69024672T2 (de) Sprays zur Behandlung von Infektionen des Tractus Respiratorius
DE60209511T2 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
EP0316633B1 (de) Azelastin enthaltende Arzneimittel zur Anwendung in der Nase und/oder am Auge
DE3335086C2 (enExample)
DE1492015A1 (de) Verbesserte Verabreichungsform pharmazeutischer Praeparate
EP0773022B3 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensaüre
DE69033112T2 (de) Zink enthaltende Sprays
DE112019000683T5 (de) Intranasale epinephrin-formulierungen und verfahren zur behandlung von erkrankungen
DE69318212T2 (de) Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie
DE68902300T2 (de) Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.
DE10337186A1 (de) Wässrige Wirkstoff-Lösung
DE69527713T2 (de) Verbindunngen und zusammensetzungen zur verabreichung via inhalation und insufflierung
DE3601923A1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung
DE19541919A1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE60101979T2 (de) Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel
DE68915203T2 (de) Pharmazeutische Mischungen.
DE60023341T2 (de) Orale lösung enthaltend galanthamine und ein süssungsmittel
CN107569454B (zh) 一种盐酸奥洛他定鼻喷雾剂及其制备方法
DE3034975A1 (de) Arzneimittelkombination zur behandlung infektioeser atemwegerkrankungen
EP0403575B1 (de) Acyl-carnitin zur behandlung und zur verhütung von virusinfektionen
DE69616335T2 (de) Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
EP1150660B1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
DE69917658T3 (de) Micronisierte pharmazeutische zusammensetzungen
DE3141970A1 (de) Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition